Anika Therapeutics Inc (ANIK) 41.30 $ANIK
Anika Therapeutics Announces Date of Fourth-Quarter and Year-End 2014 Financial Results Conference Call
Business Wire - Thu Feb 12, 3:05PM CST
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its fourth-quarter and year-end 2014 financial results after the close of the market on Wednesday, February 25, 2015. The company plans to hold a conference call the next day, Thursday, February 26 at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.
ANIK: 41.30 (-0.17)
Anika Therapeutics reports Cingal's regulatory submissions in the US and Europe
M2 - Thu Feb 12, 5:11AM CST
Tissue protection company Anika Therapeutics (NasdaqGS:ANIK) said on Wednesday that it has filed regulatory submissions in both the US and Europe seeking the approval of its novel HA plus steroid single-injection treatment for osteoarthritis of the knee, Cingal.
ANIK: 41.30 (-0.17)
Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), CBYL: (), ANIK: 41.30 (-0.17)
Collagen and HA-Based Biomaterials - Global Strategic Business Report 2015: Increasing Preference for Shorter and Convenient Treatment Options
M2 - Wed Feb 11, 2:30PM CST
Research and Markets (http://www.researchandmarkets.com/research/hsppk2/collagen_and) has announced the addition of the "Collagen and HA-Based Biomaterials - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Collagen and HA-Based Biomaterials in US$ Thousands by the following Product Segments: Collagen-based Biomaterials (Urinary Incontinence, Corneal Shields, Facial Aesthetic Dermal Fillers, Wound Dressings), and Hyaluronic Acid-based Biomaterials (Viscosupplements, Viscoelastics, and Facial Aesthetic Dermal Fillers). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 55 companies including many key and niche players such as: - Abbott Medical Optics, Inc. (US) - Alcon Laboratories, Inc. (US) - Allergan, Inc. (US) - Anika Therapeutics, Inc. (US) - Bausch & Lomb, Inc. (US) - Collagen Solutions Plc. (UK) - Galderma (Switzerland) - Genzyme (US) - Lifecore Biomedical, LLC (US) - Seikagaku Corp. (Japan) - Teijin Pharma Limited (Japan) Key Topics Covered: 1. GLOBAL MARKET OVERVIEW 2. MARKET TRENDS AND ISSUES 3. BIOMATERIALS A BRIEF OVERVIEW 4. SEGMENT OVERVIEW 5. PRODUCT INTRODUCTIONS/INNOVATIONS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT KEY PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 55 (including Divisions/Subsidiaries 60) - The United States (36) - Canada (1) - Japan (3) - Europe (18) - France (1) - Germany (4) - The United Kingdom (5) - Italy (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/hs...llagen_and
AGN: 229.49 (+1.87), ANIK: 41.30 (-0.17)
Anika Therapeutics Announces Regulatory Submissions with U.S. FDA and European Regulatory Authorities for Cingal(R)
Business Wire - Wed Feb 11, 1:00PM CST
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair, based on hyaluronic acid (HA) technology, today announced that it has filed regulatory submissions in both the United States and Europe seeking the approval of Cingal, the Company's novel HA plus steroid single-injection treatment for osteoarthritis of the knee. Anika submitted its application for CE Mark approval to commercialize Cingal in the European Union and also filed its premarket approval application (PMA) with the U.S. Food and Drug Administration to allow for marketing and distribution in the United States.
ANIK: 41.30 (-0.17)
World Collagen and HA-Based Biomaterials Industry
PR Newswire - Thu Feb 05, 1:23PM CST
This report analyzes the worldwide markets for Collagen and HA-Based Biomaterials in US$ Thousands by the following Product Segments: Collagen-based Biomaterials (Urinary Incontinence, Corneal Shields, Facial Aesthetic Dermal Fillers, Wound Dressings), and Hyaluronic Acid-based Biomaterials (Viscosupplements, Viscoelastics, and Facial Aesthetic Dermal Fillers). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 55 companies including many key and niche players such as -
AGN: 229.49 (+1.87), ANIK: 41.30 (-0.17)
Flexion patient dosing underway in lead product study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:27PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), CBYL: (), ANIK: 41.30 (-0.17)
Carbylan Therapeutics on deck for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:13PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), ANIK: 41.30 (-0.17), CBYL: ()
European Orthopedic Soft Tissue Repair & Sports Medicine Market 2014-2020
M2 - Thu Jan 15, 9:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lgjtzx/european) has announced the addition of the "European Orthopedic Soft Tissue Repair & Sports Medicine Market - 2014" report to their offering. The orthopedic soft tissue repair and sports medicine market includes rotator cuff repair, shoulder labrum repair, ACL/PCL reconstruction, ACL/PCL fixation, meniscal repair, cartilage repair, rotator cuff graft reinforcement and hip arthroscopy. All of these segments have been affected by the 2011 economic downturn. This caused declining ASPs, which were still observed in 2013. This trend is expected to continue for the rest of the forecast period. There was also a decline in procedure numbers; however, procedure numbers have quickly recovered and will continue to recover over the forecast period for the most influenced market segments. In 2013, most of the segments analyzed in this report were already on a path to recovery and showed market growth. By the end of the forecast period, in 2020, all of the segments in the European orthopedic soft tissue and sports medicine market will be growing. Report Highlights: - Includes additional information on reimbursement changes - New segments, hip arthroscopy, rotator cuff graft reinforcement, ACL/PCL reconstruction (Large over 110 million) and cartilage repair. - Full competitive analysis of leading competitors - Cartilage repair and graft reinforcement are both emerging markets. - We look at the allograft market, which is very different from the USA, since in Europe you cannot charge for an allograft from donor, you can only charge for procedure and materials used. - Discusses differences in growth and price between tibial and femoral interference screws and intratunnel (sheath and screw) fixation. As well as cortical fixation, cross pins and washer and posts. Key Topics Covered: - Executive Summary - Research Methodology - European Orthopedic Soft Tissue Repair Market - Country Profiles - Acl/Pcl Reconstruction Market - Acl/Pcl Fixation Device Market - Cartilage Repair Market - Meniscal Repair Market - Rotator Cuff Repair Market - Shoulder Labrum Repair Market - Hip Arthroscopy Market Companies Mentioned - Anika Therapeutics - Arthrex - Arthrocare - Artimplant - Biomet - ConMed Linvatec - DePuy Mitek - Genzyme - Genzyme - Karl Storz - Smith & Nephew - Stryker - TETEC AG/B. Braun - TiGenix - Tornier - Wright Medical - Zimmer For more information visit http://www.researchandmarkets.com/research/lgjtzx/european
SNN: 35.82 (-0.28), ANIK: 41.30 (-0.17)
2015 U.S. Orthopedic Biomaterials Market Report
M2 - Fri Jan 09, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z9x9b/u_s_orthopedic) has announced the addition of the "U.S. Orthopedic Biomaterials Market - 2015" report to their offering. The U.S. orthopedic biomaterials market includes bone graft substitutes, growth factors, orthopedic stem cells, cell therapy, hyaluronic acid viscosupplementation, cartilage repair and machined bone allografts. The fastest growing segments involve stem cells, namely the segments for stem cell bone grafts and concentrated bone marrow. The products within these markets offer the greatest regenerative potential for healing bone. Orthopedic biomaterial products compete with products that are more established and less expensive. Thus, clinical evidence is often an important deciding factor for orthopedic biomaterials over conventional forms of therapy especially in regards to reimbursement. However, the promise seen in some products such as bone marrow concentrate generates growth despite a lack of clinical evidence and reimbursement. Report Contents: - Competitor Analysis - Identified Strategic Opportunities - Indepth Procedure Volumes - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback and Market Monitoring Report Highlights: - A wide range of devices/treatments covered in the report focused around regenerative and resorbable orthopedic options - Complementary products such as PRP (provides growth factor) and BMC (provides stem cells) used in conjunction with bone graft substitutes. Allows the graft to compete with growth factor and stem cell bone grafts - Highlights trend towards demineralized bone matrices and synthetics - Competitive analysis broken down for each type: allograft, DBM and synthetics - A wide range of devices/treatments covered in the report focused around regenerative and resorbable orthopedic options - Cartilage repair market includes two new segments: juvenile particulated allograft (Zimmer's DeNovo) and microfracture adjunct (Arthrex's BioCartilage) Key Topics Covered: 1. Executive Summary 2. Research Methodology 3. U.S. Orthopedic Biomaterials Market Overview 4. Procedure Numbers 5. Orthopedic Bone Graft Substitute Market 6. Orthopedic Growth Factor Market 7. Orthopedic Stem Cell Market 8. Orthopedic Cell Therapy Market 9. Orthopedic Hyaluronic Acid Viscosupplementation Market 10. Orthopedic Cartilage Repair Market 11. Spinal Machined Bone Allograft Market Companies Mentioned - Aastrom - Allosource - Anika Therapeutics - Artrhex - Baxter - Biomet - Bioventus - DePuy Synthes - Exactech - Ferring Pharmaceuticals - Fidia Pharmaceuticals - Genzyme - Harvest - Integra LifeSciences - MTF - Medtronic - NuVasive - Orthofix - RTI Surgical - Stryker - Wright Medical - Zimmer For more information visit http://www.researchandmarkets.com/research/8z...orthopedic
MDT: 75.26 (+0.33), ANIK: 41.30 (-0.17)
U.S. Orthopedic Biomaterials Market - 2015 Executive Summary
M2 - Fri Jan 09, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/d37fj4/u_s_orthopedic) has announced the addition of the "U.S. Orthopedic Biomaterials Market - 2015 (Executive Summary)" report to their offering. The fastest growing segments involve stem cells, namely the segments for stem cell bone grafts and concentrated bone marrow. The products within these markets offer the greatest regenerative potential for healing bone. Orthopedic biomaterial products compete with products that are more established and less expensive. Thus, clinical evidence is often an important deciding factor for orthopedic biomaterials over conventional forms of therapy especially in regards to reimbursement. However, the promise seen in some products such as bone marrow concentrate generates growth despite a lack of clinical evidence and reimbursement. Key Topics Covered: - U.S. Market For Orthopedic Biomaterials - Orthopedic Bone Graft Substitute Market - Orthopedic Growth Factor Market - Orthopedic Stem Cell Market - Orthopedic Cell Therapy Market - Orthopedic Hyaluronic Acid Viscosupplementation Market - Orthopedic Cartilage Repair Market - Spinal Machined Bone Allograft Market - Leading Competitors - Aastrom - Allosource - Anika Therapeutics - Artrhex - Baxter - Biomet - Bioventus - DePuy Synthes - Exactech - Ferring Pharmaceuticals - Fidia Pharmaceuticals - Genzyme - Harvest - Integra LifeSciences - MTF - Medtronic - NuVasive - Orthofix - RTI Surgical - Stryker - Wright Medical - Zimmer For more information visit http://www.researchandmarkets.com/research/d3...orthopedic
MDT: 75.26 (+0.33), ANIK: 41.30 (-0.17)
Seeking Alpha's Biotech Weekly: AbbVie Slaps Gilead, Achillion's 'Nuc' Power, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Dec 26, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
MGNX: 34.09 (+0.10), CYTK: 7.78 (+1.29), JNJ: 99.62 (+1.18), ESRX: 84.90 (+0.40), ALNY: 95.54 (+1.67), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), ANIK: 41.30 (-0.17)
Anika Therapeutics: U.S. Approval To Drive Profit And Valuation
KEMS Research - Seeking Alpha - Tue Dec 23, 5:45AM CST
Description Anika Therapeutics (NASDAQ: ANIK ) is a small cap, biotech company focused on commercializing hyaluronic acid (HA) based therapeutic solutions. HA is naturally present in human bodies and is found primarily in the skin,...
ANIK: 41.30 (-0.17), SNY: 49.42 (+0.82)
United States Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry Analytics 2014-2021 - Market to reach $39.5 billion by 2021
M2 - Mon Dec 15, 8:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/s847lc/vaccines_skin) has announced the addition of Plunkett Research Ltd's new report "Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.) to reach $39.5 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Anika Therapeutics Inc - CSL Behring LLC - Emergent BioSolutions Inc - Halozyme Therapeutics Inc - LifeCell Corporation - Lifecore Biomedical Inc - MiMedx Group Inc - Organogenesis Inc - RTI Biologics Inc - Zoetis Inc For more information visit http://www.researchandmarkets.com/research/s8...cines_skin Source: Plunkett Research Ltd
ZTS: 45.46 (-0.33), RTIX: 5.54 (+0.19), HALO: 14.73 (+0.23), EBS: 28.76 (-0.12), ANIK: 41.30 (-0.17), MDXG: 8.65 (+0.23)
3 Biotech Stocks to Buy in December
Motley Fool Staff - Motley Fool - Wed Dec 10, 8:18AM CST
Source: Biogen Idec As the year begins to come to a close, biotechnology investors are right to wonder what stocks may be worth owning as we head into 2015. We asked three of our Motley Fool analysts to tell us which three biotechnology stocks will...
BIIB: 391.66 (-0.45), SNY: 49.42 (+0.82), ANIK: 41.30 (-0.17), REGN: 402.40 (+0.66)
Stocks To Buy In Forbes' Best Small Companies List
MagicDiligence - Seeking Alpha - Thu Nov 20, 7:34AM CST
Every year in the fall, Forbes publishes its annual list of America's Best Small Companies : 100 public companies with sales under $1 billion. Forbes looks for small companies with strong sales growth, expanding profit margins, and high returns on...
MYGN: 34.03 (+0.40), SYNT: 45.23 (+0.46), SLI: 38.75 (-0.42), MED: 31.55 (-1.31), AFOP: 16.51 (+0.03), IPCM: 42.99 (+0.66), CPSI: 53.11 (+0.26), ANIK: 41.30 (-0.17), RGR: 43.60 (+0.61), RPXC: 13.94 (+0.42)
Anika Therapeutics Earnings Review: 19 Days after Announcement Shares Down 3.0% (ANIK)
Comtex SmarTrend(R) - Mon Nov 17, 1:19PM CST
When Anika Therapeutics (NASDAQ:ANIK) reported earnings two weeks ago on October 29th, 2014, analysts, on average, expected the company to report earnings of $0.33 on sales of $20.7 million. The company actually reported EPS of $0.40 on sales of $22.1 million, beating EPS estimates by $0.08 and beating revenue estimates by $1.4 million. Shares of Anika Therapeutics have slipped from $40.79 to $39.57, representing a loss of 3.0%, since the company reported earnings 19 days ago.
ANIK: 41.30 (-0.17)
Update: Anika Therapeutics Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Tue Nov 11, 1:21PM CST
ANIK: 41.30 (-0.17)
Global Anti-Adhesion Products Industry
PR Newswire - Tue Nov 11, 10:23AM CST
This report analyzes the worldwide markets for Anti-Adhesion Products in US$ Thousands by the following three major Application Areas: General/Abdominal Surgery, Pelvic/Gynecological Surgery, and Other Surgical Procedures. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 19 companies including many key and niche players such as -
ANIK: 41.30 (-0.17)
Center for Medicare & Medicaid Services Announces That a Unique Reimbursement Code is Assigned to Anika's MONOVISC(R) Product
Business Wire - Mon Nov 10, 3:05PM CST
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that the Center for Medicare & Medicaid Services ("CMS"
has assigned a unique Healthcare Common Procedure Coding System ("HCPCS" code, or J-Code, to its product MONOVISC(R). The issuance of this code by CMS sets national Medicare reimbursement rates for the product. The new J-Code becomes effective on January 1, 2015.
ANIK: 41.30 (-0.17)
Anika Therapeutics Announces Date of Fourth-Quarter and Year-End 2014 Financial Results Conference Call
Business Wire - Thu Feb 12, 3:05PM CST
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its fourth-quarter and year-end 2014 financial results after the close of the market on Wednesday, February 25, 2015. The company plans to hold a conference call the next day, Thursday, February 26 at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.
ANIK: 41.30 (-0.17)
Anika Therapeutics reports Cingal's regulatory submissions in the US and Europe
M2 - Thu Feb 12, 5:11AM CST
Tissue protection company Anika Therapeutics (NasdaqGS:ANIK) said on Wednesday that it has filed regulatory submissions in both the US and Europe seeking the approval of its novel HA plus steroid single-injection treatment for osteoarthritis of the knee, Cingal.
ANIK: 41.30 (-0.17)
Anika Therapeutics files Cingal regulatory apps in U.S. and Europe
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 2:42PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), CBYL: (), ANIK: 41.30 (-0.17)
Collagen and HA-Based Biomaterials - Global Strategic Business Report 2015: Increasing Preference for Shorter and Convenient Treatment Options
M2 - Wed Feb 11, 2:30PM CST
Research and Markets (http://www.researchandmarkets.com/research/hsppk2/collagen_and) has announced the addition of the "Collagen and HA-Based Biomaterials - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Collagen and HA-Based Biomaterials in US$ Thousands by the following Product Segments: Collagen-based Biomaterials (Urinary Incontinence, Corneal Shields, Facial Aesthetic Dermal Fillers, Wound Dressings), and Hyaluronic Acid-based Biomaterials (Viscosupplements, Viscoelastics, and Facial Aesthetic Dermal Fillers). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 55 companies including many key and niche players such as: - Abbott Medical Optics, Inc. (US) - Alcon Laboratories, Inc. (US) - Allergan, Inc. (US) - Anika Therapeutics, Inc. (US) - Bausch & Lomb, Inc. (US) - Collagen Solutions Plc. (UK) - Galderma (Switzerland) - Genzyme (US) - Lifecore Biomedical, LLC (US) - Seikagaku Corp. (Japan) - Teijin Pharma Limited (Japan) Key Topics Covered: 1. GLOBAL MARKET OVERVIEW 2. MARKET TRENDS AND ISSUES 3. BIOMATERIALS A BRIEF OVERVIEW 4. SEGMENT OVERVIEW 5. PRODUCT INTRODUCTIONS/INNOVATIONS 6. RECENT INDUSTRY ACTIVITY 7. FOCUS ON SELECT KEY PLAYERS 8. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 55 (including Divisions/Subsidiaries 60) - The United States (36) - Canada (1) - Japan (3) - Europe (18) - France (1) - Germany (4) - The United Kingdom (5) - Italy (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/hs...llagen_and
AGN: 229.49 (+1.87), ANIK: 41.30 (-0.17)
Anika Therapeutics Announces Regulatory Submissions with U.S. FDA and European Regulatory Authorities for Cingal(R)
Business Wire - Wed Feb 11, 1:00PM CST
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair, based on hyaluronic acid (HA) technology, today announced that it has filed regulatory submissions in both the United States and Europe seeking the approval of Cingal, the Company's novel HA plus steroid single-injection treatment for osteoarthritis of the knee. Anika submitted its application for CE Mark approval to commercialize Cingal in the European Union and also filed its premarket approval application (PMA) with the U.S. Food and Drug Administration to allow for marketing and distribution in the United States.
ANIK: 41.30 (-0.17)
World Collagen and HA-Based Biomaterials Industry
PR Newswire - Thu Feb 05, 1:23PM CST
This report analyzes the worldwide markets for Collagen and HA-Based Biomaterials in US$ Thousands by the following Product Segments: Collagen-based Biomaterials (Urinary Incontinence, Corneal Shields, Facial Aesthetic Dermal Fillers, Wound Dressings), and Hyaluronic Acid-based Biomaterials (Viscosupplements, Viscoelastics, and Facial Aesthetic Dermal Fillers). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 55 companies including many key and niche players such as -
AGN: 229.49 (+1.87), ANIK: 41.30 (-0.17)
Flexion patient dosing underway in lead product study
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 3:27PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), CBYL: (), ANIK: 41.30 (-0.17)
Carbylan Therapeutics on deck for IPO
Seeking Alpha - at Seeking Alpha - Tue Jan 27, 12:13PM CST
MNK: 115.01 (+2.51), FLXN: 21.29 (+0.28), XENE: 16.37 (+0.17), HZNP: 16.84 (-0.41), AMPE: 5.85 (-0.05), ANIK: 41.30 (-0.17), CBYL: ()
European Orthopedic Soft Tissue Repair & Sports Medicine Market 2014-2020
M2 - Thu Jan 15, 9:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lgjtzx/european) has announced the addition of the "European Orthopedic Soft Tissue Repair & Sports Medicine Market - 2014" report to their offering. The orthopedic soft tissue repair and sports medicine market includes rotator cuff repair, shoulder labrum repair, ACL/PCL reconstruction, ACL/PCL fixation, meniscal repair, cartilage repair, rotator cuff graft reinforcement and hip arthroscopy. All of these segments have been affected by the 2011 economic downturn. This caused declining ASPs, which were still observed in 2013. This trend is expected to continue for the rest of the forecast period. There was also a decline in procedure numbers; however, procedure numbers have quickly recovered and will continue to recover over the forecast period for the most influenced market segments. In 2013, most of the segments analyzed in this report were already on a path to recovery and showed market growth. By the end of the forecast period, in 2020, all of the segments in the European orthopedic soft tissue and sports medicine market will be growing. Report Highlights: - Includes additional information on reimbursement changes - New segments, hip arthroscopy, rotator cuff graft reinforcement, ACL/PCL reconstruction (Large over 110 million) and cartilage repair. - Full competitive analysis of leading competitors - Cartilage repair and graft reinforcement are both emerging markets. - We look at the allograft market, which is very different from the USA, since in Europe you cannot charge for an allograft from donor, you can only charge for procedure and materials used. - Discusses differences in growth and price between tibial and femoral interference screws and intratunnel (sheath and screw) fixation. As well as cortical fixation, cross pins and washer and posts. Key Topics Covered: - Executive Summary - Research Methodology - European Orthopedic Soft Tissue Repair Market - Country Profiles - Acl/Pcl Reconstruction Market - Acl/Pcl Fixation Device Market - Cartilage Repair Market - Meniscal Repair Market - Rotator Cuff Repair Market - Shoulder Labrum Repair Market - Hip Arthroscopy Market Companies Mentioned - Anika Therapeutics - Arthrex - Arthrocare - Artimplant - Biomet - ConMed Linvatec - DePuy Mitek - Genzyme - Genzyme - Karl Storz - Smith & Nephew - Stryker - TETEC AG/B. Braun - TiGenix - Tornier - Wright Medical - Zimmer For more information visit http://www.researchandmarkets.com/research/lgjtzx/european
SNN: 35.82 (-0.28), ANIK: 41.30 (-0.17)
2015 U.S. Orthopedic Biomaterials Market Report
M2 - Fri Jan 09, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/8z9x9b/u_s_orthopedic) has announced the addition of the "U.S. Orthopedic Biomaterials Market - 2015" report to their offering. The U.S. orthopedic biomaterials market includes bone graft substitutes, growth factors, orthopedic stem cells, cell therapy, hyaluronic acid viscosupplementation, cartilage repair and machined bone allografts. The fastest growing segments involve stem cells, namely the segments for stem cell bone grafts and concentrated bone marrow. The products within these markets offer the greatest regenerative potential for healing bone. Orthopedic biomaterial products compete with products that are more established and less expensive. Thus, clinical evidence is often an important deciding factor for orthopedic biomaterials over conventional forms of therapy especially in regards to reimbursement. However, the promise seen in some products such as bone marrow concentrate generates growth despite a lack of clinical evidence and reimbursement. Report Contents: - Competitor Analysis - Identified Strategic Opportunities - Indepth Procedure Volumes - Market Overview by Segment - Trend Analysis by Segment - Market Drivers & Limiters - Mergers & Acquisitions - Customer Feedback and Market Monitoring Report Highlights: - A wide range of devices/treatments covered in the report focused around regenerative and resorbable orthopedic options - Complementary products such as PRP (provides growth factor) and BMC (provides stem cells) used in conjunction with bone graft substitutes. Allows the graft to compete with growth factor and stem cell bone grafts - Highlights trend towards demineralized bone matrices and synthetics - Competitive analysis broken down for each type: allograft, DBM and synthetics - A wide range of devices/treatments covered in the report focused around regenerative and resorbable orthopedic options - Cartilage repair market includes two new segments: juvenile particulated allograft (Zimmer's DeNovo) and microfracture adjunct (Arthrex's BioCartilage) Key Topics Covered: 1. Executive Summary 2. Research Methodology 3. U.S. Orthopedic Biomaterials Market Overview 4. Procedure Numbers 5. Orthopedic Bone Graft Substitute Market 6. Orthopedic Growth Factor Market 7. Orthopedic Stem Cell Market 8. Orthopedic Cell Therapy Market 9. Orthopedic Hyaluronic Acid Viscosupplementation Market 10. Orthopedic Cartilage Repair Market 11. Spinal Machined Bone Allograft Market Companies Mentioned - Aastrom - Allosource - Anika Therapeutics - Artrhex - Baxter - Biomet - Bioventus - DePuy Synthes - Exactech - Ferring Pharmaceuticals - Fidia Pharmaceuticals - Genzyme - Harvest - Integra LifeSciences - MTF - Medtronic - NuVasive - Orthofix - RTI Surgical - Stryker - Wright Medical - Zimmer For more information visit http://www.researchandmarkets.com/research/8z...orthopedic
MDT: 75.26 (+0.33), ANIK: 41.30 (-0.17)
U.S. Orthopedic Biomaterials Market - 2015 Executive Summary
M2 - Fri Jan 09, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/d37fj4/u_s_orthopedic) has announced the addition of the "U.S. Orthopedic Biomaterials Market - 2015 (Executive Summary)" report to their offering. The fastest growing segments involve stem cells, namely the segments for stem cell bone grafts and concentrated bone marrow. The products within these markets offer the greatest regenerative potential for healing bone. Orthopedic biomaterial products compete with products that are more established and less expensive. Thus, clinical evidence is often an important deciding factor for orthopedic biomaterials over conventional forms of therapy especially in regards to reimbursement. However, the promise seen in some products such as bone marrow concentrate generates growth despite a lack of clinical evidence and reimbursement. Key Topics Covered: - U.S. Market For Orthopedic Biomaterials - Orthopedic Bone Graft Substitute Market - Orthopedic Growth Factor Market - Orthopedic Stem Cell Market - Orthopedic Cell Therapy Market - Orthopedic Hyaluronic Acid Viscosupplementation Market - Orthopedic Cartilage Repair Market - Spinal Machined Bone Allograft Market - Leading Competitors - Aastrom - Allosource - Anika Therapeutics - Artrhex - Baxter - Biomet - Bioventus - DePuy Synthes - Exactech - Ferring Pharmaceuticals - Fidia Pharmaceuticals - Genzyme - Harvest - Integra LifeSciences - MTF - Medtronic - NuVasive - Orthofix - RTI Surgical - Stryker - Wright Medical - Zimmer For more information visit http://www.researchandmarkets.com/research/d3...orthopedic
MDT: 75.26 (+0.33), ANIK: 41.30 (-0.17)
Seeking Alpha's Biotech Weekly: AbbVie Slaps Gilead, Achillion's 'Nuc' Power, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Dec 26, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
MGNX: 34.09 (+0.10), CYTK: 7.78 (+1.29), JNJ: 99.62 (+1.18), ESRX: 84.90 (+0.40), ALNY: 95.54 (+1.67), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), ANIK: 41.30 (-0.17)
Anika Therapeutics: U.S. Approval To Drive Profit And Valuation
KEMS Research - Seeking Alpha - Tue Dec 23, 5:45AM CST
Description Anika Therapeutics (NASDAQ: ANIK ) is a small cap, biotech company focused on commercializing hyaluronic acid (HA) based therapeutic solutions. HA is naturally present in human bodies and is found primarily in the skin,...
ANIK: 41.30 (-0.17), SNY: 49.42 (+0.82)
United States Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry Analytics 2014-2021 - Market to reach $39.5 billion by 2021
M2 - Mon Dec 15, 8:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/s847lc/vaccines_skin) has announced the addition of Plunkett Research Ltd's new report "Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.) to reach $39.5 billion by 2021 Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked - Anika Therapeutics Inc - CSL Behring LLC - Emergent BioSolutions Inc - Halozyme Therapeutics Inc - LifeCell Corporation - Lifecore Biomedical Inc - MiMedx Group Inc - Organogenesis Inc - RTI Biologics Inc - Zoetis Inc For more information visit http://www.researchandmarkets.com/research/s8...cines_skin Source: Plunkett Research Ltd
ZTS: 45.46 (-0.33), RTIX: 5.54 (+0.19), HALO: 14.73 (+0.23), EBS: 28.76 (-0.12), ANIK: 41.30 (-0.17), MDXG: 8.65 (+0.23)
3 Biotech Stocks to Buy in December
Motley Fool Staff - Motley Fool - Wed Dec 10, 8:18AM CST
Source: Biogen Idec As the year begins to come to a close, biotechnology investors are right to wonder what stocks may be worth owning as we head into 2015. We asked three of our Motley Fool analysts to tell us which three biotechnology stocks will...
BIIB: 391.66 (-0.45), SNY: 49.42 (+0.82), ANIK: 41.30 (-0.17), REGN: 402.40 (+0.66)
Stocks To Buy In Forbes' Best Small Companies List
MagicDiligence - Seeking Alpha - Thu Nov 20, 7:34AM CST
Every year in the fall, Forbes publishes its annual list of America's Best Small Companies : 100 public companies with sales under $1 billion. Forbes looks for small companies with strong sales growth, expanding profit margins, and high returns on...
MYGN: 34.03 (+0.40), SYNT: 45.23 (+0.46), SLI: 38.75 (-0.42), MED: 31.55 (-1.31), AFOP: 16.51 (+0.03), IPCM: 42.99 (+0.66), CPSI: 53.11 (+0.26), ANIK: 41.30 (-0.17), RGR: 43.60 (+0.61), RPXC: 13.94 (+0.42)
Anika Therapeutics Earnings Review: 19 Days after Announcement Shares Down 3.0% (ANIK)
Comtex SmarTrend(R) - Mon Nov 17, 1:19PM CST
When Anika Therapeutics (NASDAQ:ANIK) reported earnings two weeks ago on October 29th, 2014, analysts, on average, expected the company to report earnings of $0.33 on sales of $20.7 million. The company actually reported EPS of $0.40 on sales of $22.1 million, beating EPS estimates by $0.08 and beating revenue estimates by $1.4 million. Shares of Anika Therapeutics have slipped from $40.79 to $39.57, representing a loss of 3.0%, since the company reported earnings 19 days ago.
ANIK: 41.30 (-0.17)
Update: Anika Therapeutics Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Tue Nov 11, 1:21PM CST
ANIK: 41.30 (-0.17)
Global Anti-Adhesion Products Industry
PR Newswire - Tue Nov 11, 10:23AM CST
This report analyzes the worldwide markets for Anti-Adhesion Products in US$ Thousands by the following three major Application Areas: General/Abdominal Surgery, Pelvic/Gynecological Surgery, and Other Surgical Procedures. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 19 companies including many key and niche players such as -
ANIK: 41.30 (-0.17)
Center for Medicare & Medicaid Services Announces That a Unique Reimbursement Code is Assigned to Anika's MONOVISC(R) Product
Business Wire - Mon Nov 10, 3:05PM CST
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that the Center for Medicare & Medicaid Services ("CMS"
has assigned a unique Healthcare Common Procedure Coding System ("HCPCS" code, or J-Code, to its product MONOVISC(R). The issuance of this code by CMS sets national Medicare reimbursement rates for the product. The new J-Code becomes effective on January 1, 2015. ANIK: 41.30 (-0.17)
